Imunon, Inc.
IMNN Healthcare Biotechnology
Imunon, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $500,000.00. In the quarter to June 2026, EPS grew 71.1% and free cash flow fell 4.24%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow IMNN
Imunon, Inc. (IMNN) EV/Sales
As of 16 October 2026, Imunon, Inc. (IMNN) trades at a EV/Sales of 8.0×. Over the past ten years it has ranged from −50.0× (September 2022) to 256× (June 2020); the current reading is higher than 31% of that period. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2022 | −37.8× | — |
| FY2021 | 0.9× | (95.28%) |
| FY2020 | 18.9× | (68.93%) |
| FY2019 | 60.9× | 359.37% |
| FY2018 | 13.3× | — |
| FY2017 | −2.7× | — |
| FY2016 | 10.7× | (78.07%) |
| FY2015 | 48.7× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2022 | −37.8× | — |
| Sep 2022 | −40.2× | — |
| Jun 2022 | −46.6× | — |
| Mar 2022 | −12.4× | — |
| 28 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CANF Can-Fite Biopharma Ltd compare | −8.6× |
| EVGN Evogene Ltd. compare | −2.8× |
| ENVB Enveric Biosciences, Inc. compare | −0.1× |
| NRSN NeuroSense Therapeutics Ltd. compare | n/m |
| ALZN Alzamend Neuro, Inc. compare | n/m |
| TRAW Traws Pharma, Inc. compare | 0.3× |
| LEXX Lexaria Bioscience Corp. compare | 2.4× |
| IMNN Imunon, Inc. | 8.0× |
| ORGS Orgenesis Inc. compare | 15.7× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)